In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott: We Do Deals

Executive Summary

Abbott's recent co-promotion with Boehringer Ingelheim is just one more in a series of events to suggest that its new top managers are bringing big changes to this tradition-bound company. In particular, Abbott no longer seems to be forcing deals to pass extraordinary economic hurdles (its finance department always used high cost estimates and low revenue projections to vet potential in-licensing candidates). The company's recognizing that with its anemic pipeline and more aggressive licensers, it's going to have to ante up to stay in the game.

You may also be interested in...

Vysis's Ship Comes In

Not too long ago, Vysis was just one of dozens of struggling genomic start-ups. Now, however, with its pending acquisition by Abbott Laboratories, it is a poster child for genomics success. Abbott is betting on the potential of Vysis's core position in fluorescent in situ hybridization (FISH) as a diagnostic tool, which allows users to evaluate disease based on changes at the chromosomal level. Abbott has been marketing Vysis's FISH test for the HER2 gene and since this summer.

December ANDA Rush Is Largest In Two Years

December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.

Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM

Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts